| 143 | Adenovirus types 4 and 7Adenovirus, type 4 and type 7, live, oralThis vaccine is administered as 2 tablets. | — |
| 318 | Anthrax, post-exposure prophylaxisAnthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxisNational stockpile vaccine (Cyfendus) | — |
| 24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxisAnthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis | — |
| 19 | BCGBacillus Calmette-Guerin vaccine | India UIP, India IAP |
| 317 | Chikungunya live attenuated vaccine, 0.5 mL, PFChikungunya, live attenuated vaccine, 0.5 mL, preservative freeChikungunya Vaccine | — |
| 329 | Chikungunya, VLP, recombinant, 0.8 mL, PFChikungunya, virus-like particle (VLP), recombinant vaccine, 0.8 mL, preservative free | — |
| 174 | cholera, live attenuated | — |
| 334 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL doseModerna monovalent new formulation mNEXSPIKE, starting Fall 2025, ages 12 yrs and older, BLA | — |
| 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL doseModerna Fall Seasonal 6 months through 11 years of age | — |
| 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL doseModerna Fall Seasonal 12 years and older | — |
| 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dosePfizer Fall Seasonal 5 years through 11 years of age | — |
| 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dosePfizer Fall Seasonal 12 years and older | — |
| 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mLSARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL doseNovavax Fall Seasonal 12 years and older | — |
| 56 | dengue fever tetravalentdengue fever vaccine, tetravalentApplies to tetravalent product (e.g. DENGVAXIA) | — |
| 20 | DTaPdiphtheria, tetanus toxoids and acellular pertussis vaccine | Australia NIP |
| 110 | DTaP-Hep B-IPVDTaP-hepatitis B and poliovirus vaccine | — |
| 120 | DTaP-Hib-IPVdiphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) | Canada CIG |
| 130 | DTaP-IPVDiphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated | Canada CIG, Australia NIP |
| 106 | DTaP, 5 pertussis antigensdiphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens | Australia NIP |
| 146 | DTaP,IPV,Hib,HepBDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine.This vaccine is different from CVX 132. Code may be used to document non-US vaccines (e.g. Hexamin) of the same component formulation | NHS routine, Australia NIP |
| 204 | Ebola Zaire vaccine, live, recombinant, 1mL doseFDA Approved ERVEBO Vaccine. | — |
| 104 | Hep A-Hep Bhepatitis A and hepatitis B vaccine | — |
| 52 | Hep A, adulthepatitis A vaccine, adult dosage | — |
| 83 | Hep A, ped/adol, 2 dosehepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule | — |
| 8 | Hep B, adolescent or pediatrichepatitis B vaccine, pediatric or pediatric/adolescent dosageThis code applies to any standard pediatric formulation of Hepatitis B vaccine. It should not be used for the 2-dose hepatitis B schedule for adolescents (11-15 year olds). Use code 43 for that vaccine. | India UIP, India IAP, Australia NIP |
| 43 | Hep B, adulthepatitis B vaccine, adult dosageThis code applies to any standard adult dose and schedule. Also use CVX 43 for the FDA approved Recombivax HB 2-dose hepatitis B schedule for adolescents (11-15 year olds) using the adult formulation. | — |
| 44 | Hep B, high-dosage, dialysis or ICHepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patientThis code is used record patient high dosage vaccine administration for dialysis or immunocompromised patients. For NDCs that are used for both regular vaccine and dialysis/IC high-dosage schedules (e.g. Engerix-B), are mapped to both CVX 43 and CVX 44. CVX code 44 should be utilized to record dialysis/IC dosing. | — |
| 189 | HepB-CpGHepatitis B vaccine (recombinant), CpG adjuvanted | — |
| 49 | Hib (PRP-OMP)Haemophilus influenzae type b vaccine, PRP-OMP conjugate | — |
| 48 | Hib (PRP-T)Haemophilus influenzae type b vaccine, PRP-T conjugate | Australia NIP |
| 62 | HPV, quadrivalenthuman papilloma virus vaccine, quadrivalent | India UIP |
| 165 | HPV9Human Papillomavirus 9-valent vaccine | NHS routine, Canada CIG, Australia NIP |
| 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013Approved by FDA 2013, adjuvant is mixed at point of administration. | — |
| 321 | Influenza-avian, H5N8, monovalent, PFInfluenza-avian, H5N8, viral-vector, monovalent, injectable, preservative freeNovel Bird Flu H5N8 Vaccine 2024 | — |
| 322 | Influenza-avian, H5N8, monovalent, preservativeInfluenza-avian, H5N8, viral-vector, monovalent, injectable, contains preservativeNovel Bird Flu H5N8 Vaccine 2024 | — |
| 205 | Influenza, adjuvanted, quadrivalent, PFInfluenza, adjuvanted, inactivated, quadrivalent, injectable, preservative freeQuadrivalent code starting 2020/2021 season | — |
| 168 | Influenza, adjuvanted, trivalent, PFInfluenza, adjuvanted, inactivated, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season | — |
| 197 | Influenza, high-dose, quadrivalent, PFInfluenza, high-dose, split virus, quadrivalent, injectable, preservative freeQuadrivalent code starting season 2020/2021 | — |
| 135 | Influenza, high-dose, trivalent, PFInfluenza, high-dose, split virus, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season | — |
| 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | — |
| 149 | Influenza, live, quadrivalent, intranasalQuadrivalent code starting 2013/2014 season | — |
| 111 | Influenza, live, trivalent, intranasal, PFInfluenza, live, trivalent, intranasal, preservative freeHCP administered, trivalent code reactivated for 2024/2025 season | — |
| 333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PFInfluenza, live, trivalent, intranasal, self or caregiver administered, preservative freeSelf or caregiver administered, new starting 2025/2026 season | — |
| 171 | Influenza, MDCK, quadrivalent, PFInfluenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative freeQuadrivalent code starting 2016/2017 season | — |
| 186 | Influenza, MDCK, quadrivalent, preservativeInfluenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservativeQuadrivalent code starting 2017/2018 season | — |
| 153 | Influenza, MDCK, trivalent, PFInfluenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season | — |
| 320 | Influenza, MDCK, trivalent, preservativeInfluenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservativeTrivalent code starting 2024/2025 season | — |
| 338 | Influenza, mRNA, trivalent, PFInfluenza, mRNA lipid nanoparticle, trivalent, injectable, 0.38 mL dose, preservative-freemRNA influenza vaccine FDA approved 08/05/2026 starting with Fall 2026/2027 season | — |
| 185 | Influenza, recombinant, quadrivalent, PFInfluenza, recombinant, quadrivalent, injectable, preservative freeQuadrivalent code starting 2017/2018 season | — |
| 155 | Influenza, recombinant, trivalent, PFInfluenza, recombinant, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season | — |
| 231 | influenza, Southern Hemisphere, high-dose, quadrivalentinfluenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative freeTarget population 65 and older, starting Southern Hemisphere season 2023 | — |
| 337 | Influenza, Southern Hemisphere, high-dose, trivalent, PFInfluenza, Southern Hemisphere, high-dose, split virus, trivalent, 0.5 mL, injectable, preservative freeCode created starting 2026 Southern Hemisphere season | — |
| 200 | influenza, Southern Hemisphere, pediatric, preservative freeinfluenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative freePediatric dose for ages 6-35 months | — |
| 201 | Influenza, Southern Hemisphere, quadrivalent, PFInfluenza, seasonal, Southern Hemisphere, quadrivalent, 0.5 mL dose, preservative freeRepresents single dose vial | — |
| 202 | influenza, Southern Hemisphere, quadrivalent, with preservativeinfluenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservativeRepresents multi-dose vial | — |
| 331 | Influenza, Southern Hemisphere, trivalent, PFInfluenza, seasonal, Southern Hemisphere, trivalent, 0.5 mL dose, preservative freeRepresents single dose vial | — |
| 150 | Influenza, split virus, quadrivalent, PFInfluenza, split virus, quadrivalent, injectable, preservative freeQuadrivalent code starting 2013/2014 season | — |
| 158 | Influenza, split virus, quadrivalent, preservativeInfluenza, split virus, quadrivalent, injectable, contains preservativeQuadrivalent code starting 2013/2014 season | — |
| 140 | Influenza, split virus, trivalent, PFInfluenza, split virus, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season | — |
| 141 | Influenza, split virus, trivalent, preservativeInfluenza, split virus, trivalent, injectable, contains preservativeTrivalent code reactivated for 2024/2025 season | — |
| 10 | IPVpoliovirus vaccine, inactivated | India IAP, US CDC child |
| 134 | Japanese Encephalitis IMJapanese Encephalitis vaccine for intramuscular administration | — |
| 163 | meningococcal B, OMVmeningococcal B vaccine, recombinant, OMV, adjuvanted | NHS routine |
| 162 | meningococcal B, recombinantmeningococcal B vaccine, fully recombinant | — |
| 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free | NHS routine, Canada CIG, Australia NIP |
| 136 | Meningococcal MCV4Omeningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O) | Canada CIG |
| 114 | meningococcal MCV4Pmeningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P) | Canada CIG |
| 328 | Meningococcal oligosaccharide (MenACWY), (MenB), PFMeningococcal oligosaccharide conjugated (groups A, C, W, Y) and group B, 0.5 mL, preservative freeMeningococcal pentavalent vaccine strains ABCW and Y | — |
| 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PFMeningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative freeMeningococcal pentavalent vaccine strains ABCW and Y | — |
| 3 | MMRmeasles, mumps and rubella virus vaccine | India IAP, US CDC child, US CDC adult, Canada CIG, Australia NIP |
| 94 | MMRVmeasles, mumps, rubella, and varicella virus vaccine | NHS routine, Canada CIG, Australia NIP |
| 133 | Pneumococcal conjugate PCV 13pneumococcal conjugate vaccine, 13 valent | NHS routine |
| 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PFPneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free | US CDC adult, Canada CIG |
| 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PFPneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free | US CDC adult, NHS routine, Canada CIG, Australia NIP |
| 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PFPneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free | US CDC adult, Australia NIP |
| 33 | pneumococcal polysaccharide PPV23pneumococcal polysaccharide vaccine, 23 valent | NHS routine |
| 175 | Rabies - IM Diploid cell cultureHuman Rabies vaccine from human diploid cell culture | — |
| 176 | Rabies - IM fibroblast cultureHuman rabies vaccine from Chicken fibroblast culture | — |
| 119 | rotavirus, monovalentrotavirus, live, monovalent vaccine | NHS routine, Canada CIG, Australia NIP |
| 116 | rotavirus, pentavalentrotavirus, live, pentavalent vaccine | Canada CIG |
| 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PFRespiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative freeAdults 60 years and older, pregnant individuals | US CDC adult, NHS routine, Australia NIP |
| 332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PFRespiratory syncytial virus (RSV), monoclonal antibody, IgG1κ, (clesrovimab-cfor), 0.7 mL, neonate and infant, preservative freeRSV mAb for neonates and infants born during or entering first RSV season (Enflonsia) | — |
| 306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 monthsRespiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 monthsRSV monoclonal antibody (Beyfortus) | US CDC child |
| 307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 monthsRespiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 monthsRSV monoclonal antibody (Beyfortus) | US CDC child |
| 326 | RSV, mRNA, injectable, PFRespiratory syncytial virus (RSV), mRNA, injectable, preservative freemRNA RSV vaccine added 2024 | — |
| 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PFRespiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative freeAdults 60 years and older | Australia NIP |
| 9 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbedtetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) | Canada CIG |
| 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbedtetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) | Canada CIG |
| 196 | Td, adsorbed, preservative free, adult use, Lf unspecifiedtetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecifiedUsed when Td Lf specification is unknown | — |
| 115 | Tdaptetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed | India IAP, US CDC child, US CDC adult, NHS routine, Canada CIG, Australia NIP |
| 223 | Tick-borne encephalitis, inactivated, PF, 0.25mLTick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dosePediatric dose vaccine | — |
| 224 | Tick-borne encephalitis, inactivated, PF, 0.5mLTick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL doseAdult dose vaccine | — |
| 25 | typhoid, oraltyphoid vaccine, live, oral | — |
| 101 | typhoid, ViCPstyphoid Vi capsular polysaccharide vaccine | — |
| 75 | Vaccinia (smallpox, monkeypox), liveVaccinia (smallpox, monkeypox) vaccine, live | — |
| 206 | Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injectionVaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injectionAssociated to FDA US Licensed product JYNNEOS, non-US tradenames IMVANEX, IMVAMUNE. Review CDC & FDA guidance for updates regarding administration | — |
| 21 | varicellavaricella virus vaccine | India IAP, US CDC child, US CDC adult, Canada CIG |
| 37 | yellow fever liveyellow fever vaccine liveThis is the YF vaccine that has been available in the US for years. It is stabilized with sorbitol and gelatin. | — |
| 183 | Yellow fever vaccine live - altYellow fever vaccine live - alternative formulation for vaccine shortageThis CVX is associated to an FDA unapproved drug to be used when there is a drug shortage. Stabilized with sorbitol and lactose and has been used outside the US for some time. | — |
| 187 | zoster recombinantzoster vaccine recombinant | US CDC adult, NHS routine, Canada CIG, Australia NIP |